I make a donation

STEEPLE

To evaluating the impact of IV enoxaparine against HNF in elective angioplasty

Terminée

Bourses ACTION & PHRA 2022

Colloquium "La cardiologie préventive : nouveautés" (mardi 1er avril 2025)
Réservez vos places !

La Fondation de l'AP-HP attribue le Grand Prix Scientifique 2024 au Pr Gilles Montalescot

P&R Agenda
Au programme prochainement...

objectif

Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients.

date de réalisation

2004

nombre de patients

3528

nombre de centres participants

129 centers in 29 countries

type de financement

Private (Sanofi-Aventis)

Référence

NCT00077844

Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)

Study Description

The purpose of this study is to evaluate the efficacy and safety of intravenous enoxaparin versus intravenous unfractionated heparin (UFH) in patients undergoing non-emergent PCI, as assessed by measuring the incidence of non-coronary artery bypass graft (CABG) major and minor bleeding.

source clinicaltrials.gov

Publications

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention
Gilles Montalescot, Harvey D White, Richard Gallo, Marc Cohen, P Gabriel Steg, Philip E G Aylward, Christoph Bode, Massimo Chiariello, Spencer B King 3rd, Robert A Harrington, Walter J Desmet, Carlos Macaya, Steven R Steinhubl, STEEPLE Investigators
Publicated in The New England Journal of Medecine
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial
Gilles Montalescot, Marc Cohen, Genevieve Salette, Walter J Desmet, Carlos Macaya, Philip E G Aylward, Ph Gabriel Steg, Harvey D White, Richard Gallo, Steven R Steinhubl, STEEPLE Investigators
Publicated in European Heart Journal

Autres études

AMUNDSEN

En cours

A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs....

ARCACHON

En cours

To demonstrate the non-inferiority of a strategy of simple clinical follow-up (without non-invasive stress testing) in asymptomatic CAD patients with a prior history of coronary revascularization comp...

ANCHOR

En cours

Demonstrate the superiority of an association of VA-ECMO and IABP with an optimal medical treatment compared with an optimal medical treatment only in cardiogenic shock AMI patients